Published in J Pathol on May 01, 2010
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol (2011) 5.53
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
MuSiC: identifying mutational significance in cancer genomes. Genome Res (2012) 4.73
Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun (2013) 4.35
The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer (2010) 4.06
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Whole-genome characterization of chemoresistant ovarian cancer. Nature (2015) 3.06
Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell (2013) 2.81
Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature (2013) 2.78
The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol (2013) 2.47
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol (2013) 2.35
Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer (2011) 2.18
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS One (2014) 1.99
TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. J Pathol (2011) 1.94
Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol (2011) 1.87
Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene (2010) 1.73
Type-specific cell line models for type-specific ovarian cancer research. PLoS One (2013) 1.73
Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med (2015) 1.64
A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas. Cancer Cell (2015) 1.61
Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol (2011) 1.56
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer (2015) 1.53
Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. Obstet Gynecol (2014) 1.46
TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. Genome Res (2014) 1.45
Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes. J Pathol (2012) 1.41
Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A (2011) 1.36
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res (2012) 1.35
High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PLoS One (2011) 1.28
An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A (2014) 1.25
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene (2011) 1.20
Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia (2011) 1.17
Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol (2014) 1.12
Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. Genome Biol (2014) 1.11
Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat Genet (2016) 1.10
Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. Am J Pathol (2011) 1.08
Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res (2011) 1.07
Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. Hum Reprod (2013) 1.06
Minireview: animal models and mechanisms of ovarian cancer development. Endocrinology (2012) 1.04
Methylation of cell-free circulating DNA in the diagnosis of cancer. Front Mol Biosci (2015) 1.04
BRCA and Early Events in the Development of Serous Ovarian Cancer. Front Oncol (2014) 1.03
New perspectives on molecular targeted therapy in ovarian clear cell carcinoma. Br J Cancer (2013) 1.02
Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. Am J Pathol (2013) 1.01
Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des (2011) 0.99
Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma. PLoS One (2013) 0.99
Poor survival with wild-type TP53 ovarian cancer? Gynecol Oncol (2013) 0.97
Histotype-specific copy-number alterations in ovarian cancer. BMC Med Genomics (2012) 0.96
Next-Generation Sequencing of Tubal Intraepithelial Carcinomas. JAMA Oncol (2015) 0.96
The new face of ovarian cancer modeling: better prospects for detection and treatment. F1000 Med Rep (2011) 0.94
Clonal genotype and population structure inference from single-cell tumor sequencing. Nat Methods (2016) 0.93
Angiogenesis-related pathways in the pathogenesis of ovarian cancer. Int J Mol Sci (2013) 0.93
Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation. Mol Cancer (2011) 0.93
ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival. Br J Cancer (2011) 0.92
Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer. BMC Cancer (2012) 0.92
Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. Am J Surg Pathol (2015) 0.91
Epithelial ovarian cancer: An overview. World J Transl Med (2014) 0.91
Prognostic biomarkers in endometrial and ovarian carcinoma. Virchows Arch (2014) 0.90
Whole exome sequence analysis of serous borderline tumors of the ovary. Gynecol Oncol (2013) 0.90
The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome. PLoS One (2012) 0.89
Innate immune agonist, dsRNA, induces apoptosis in ovarian cancer cells and enhances the potency of cytotoxic chemotherapeutics. FASEB J (2012) 0.88
Prioritizing therapeutic targets using patient-derived xenograft models. Biochim Biophys Acta (2015) 0.88
miR-661 downregulates both Mdm2 and Mdm4 to activate p53. Cell Death Differ (2013) 0.88
Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples. PLoS One (2014) 0.88
Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Hum Mol Genet (2015) 0.88
Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. Int J Gynecol Pathol (2016) 0.88
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis (2015) 0.87
Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res (2016) 0.87
Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications. Viruses (2015) 0.87
Gene expression signature of normal cell-of-origin predicts ovarian tumor outcomes. PLoS One (2013) 0.87
Network-based survival-associated module biomarker and its crosstalk with cell death genes in ovarian cancer. Sci Rep (2015) 0.87
Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium. Oncogene (2012) 0.87
Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov (2016) 0.87
Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. Mol Cancer Ther (2013) 0.86
CD44 and p53 immunoexpression patterns in NF1 neoplasms - indicators of malignancy and infiltration. Int J Clin Exp Pathol (2010) 0.86
Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy. Am J Pathol (2011) 0.86
Lysophosphatidic Acid Initiates Epithelial to Mesenchymal Transition and Induces β-Catenin-mediated Transcription in Epithelial Ovarian Carcinoma. J Biol Chem (2015) 0.84
New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches. Biomed Res Int (2013) 0.84
Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells. Int J Cancer (2011) 0.84
Predicting survival in head and neck squamous cell carcinoma from TP53 mutation. Hum Genet (2014) 0.84
Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies. EBioMedicine (2016) 0.84
The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice. Endocrinology (2015) 0.84
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study. PLoS Med (2016) 0.83
Loss of BRCA1-A complex function in RAP80 null tumor cells. PLoS One (2012) 0.83
Discovery of prognostic factors for diagnosis and treatment of epithelial-derived ovarian cancer from laying hens. J Cancer Prev (2013) 0.83
The chicken model of spontaneous ovarian cancer. Proteomics Clin Appl (2014) 0.83
A Mouse Model That Reproduces the Developmental Pathways and Site Specificity of the Cancers Associated With the Human BRCA1 Mutation Carrier State. EBioMedicine (2015) 0.82
Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nat Commun (2015) 0.82
Role of p53 in the progression of gastric cancer. Oncotarget (2014) 0.82
Bioenergetic analysis of ovarian cancer cell lines: profiling of histological subtypes and identification of a mitochondria-defective cell line. PLoS One (2014) 0.82
Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach. BMC Res Notes (2014) 0.82
Tubal ligation and ovarian cancer risk in a large cohort: Substantial variation by histological type. Int J Cancer (2015) 0.81
Bidirectional modulation of endogenous EpCAM expression to unravel its function in ovarian cancer. Br J Cancer (2013) 0.81
Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma. Virchows Arch (2014) 0.81
Epigenetic control of autophagy by microRNAs in ovarian cancer. Biomed Res Int (2014) 0.81
Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. J Cell Mol Med (2016) 0.81
Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent disease. BMC Cancer (2012) 0.80
TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer. Nucleic Acids Res (2015) 0.80
Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers. PLoS One (2014) 0.80
Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. Sci Rep (2016) 0.79
The significance of the alteration of 8-OHdG in serous ovarian carcinoma. J Ovarian Res (2013) 0.79
Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol (2000) 128.08
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (1992) 25.54
Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (1992) 17.40
Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 10.31
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature (1995) 10.18
Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst (2005) 9.38
When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 5.86
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med (2008) 5.19
A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol (2007) 5.12
The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature (2004) 5.05
Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell (2003) 4.96
Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet (2001) 4.23
Digital karyotyping. Proc Natl Acad Sci U S A (2002) 3.96
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol (2009) 3.90
Estimation and assessment of raw copy numbers at the single locus level. Bioinformatics (2008) 3.62
Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res (2009) 3.45
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 3.17
The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol (2007) 3.02
Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol (2009) 2.94
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res (2005) 2.72
Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res (1991) 2.20
Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat Rev Cancer (2006) 2.05
Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst (2000) 1.99
p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A (1993) 1.93
Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol (1996) 1.91
Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther (2008) 1.88
Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res (1999) 1.83
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res (2009) 1.82
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene (2005) 1.80
Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res (2005) 1.80
Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer (2007) 1.70
The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol (2007) 1.70
Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain. Cell Cycle (2009) 1.57
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer (2009) 1.53
PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. Cancer Res (2008) 1.52
Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res (1991) 1.43
Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. J Natl Cancer Inst (1999) 1.38
Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. Clin Cancer Res (2008) 1.37
Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer (1995) 1.24
The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer (2000) 1.20
Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study. Gynecol Oncol (2008) 1.09
Critical evaluation of p53 as a prognostic marker in ovarian cancer. Expert Rev Mol Med (2004) 1.08
Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis. Int J Cancer (2008) 1.01
Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas. APMIS (2008) 0.99
TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study. BMC Cancer (2008) 0.94
The emerging role of the distal Fallopian tube and p53 in pelvic serous carcinogenesis. J Pathol (2010) 0.85
Signatures of mutational processes in human cancer. Nature (2013) 21.63
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
International network of cancer genome projects. Nature (2010) 20.35
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 6.41
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature (2012) 5.84
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol (2005) 5.63
Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med (2009) 5.63
Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res (2007) 5.62
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol (2007) 4.70
Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst (2002) 4.43
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell (2003) 4.33
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30
The External RNA Controls Consortium: a progress report. Nat Methods (2005) 4.24
Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer (2007) 4.06
Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell (2007) 3.89
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol (2012) 3.86
Statistical issues in the analysis of Illumina data. BMC Bioinformatics (2008) 3.66
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data. Nucleic Acids Res (2009) 3.50
Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol (2008) 3.49
Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res (2009) 3.45
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
MicroRNA: implications for cancer. Virchows Arch (2007) 3.17
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet (2010) 3.15
p300/CBP and cancer. Oncogene (2004) 3.13
Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings. Transfusion (2005) 3.08
The implications of clonal genome evolution for cancer medicine. N Engl J Med (2013) 2.78
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Chromosome abnormalities in 10 lung cancer cell lines of the NCI-H series analyzed with spectral karyotyping. Cancer Genet Cytogenet (2005) 2.70
Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci Transl Med (2012) 2.55
Sizing up miRNAs as cancer genes. Nat Med (2005) 2.48
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol (2013) 2.48
BayesPeak: Bayesian analysis of ChIP-seq data. BMC Bioinformatics (2009) 2.47
A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology (2003) 2.39
Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep (2013) 2.37
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci Transl Med (2013) 2.34
Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin Cancer Res (2014) 2.25
Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J Biol Chem (2003) 2.23
The shaping and functional consequences of the microRNA landscape in breast cancer. Nature (2013) 2.22
Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland. Breast Cancer Res (2012) 2.18
New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep (2007) 2.17
A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biol (2006) 2.17
Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res (2006) 2.16
Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A (2009) 2.12
PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer. Bioinformatics (2006) 2.12
Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer (2008) 2.11
Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age. Gynecol Oncol (2013) 2.11
The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell (2013) 2.11
A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res (2008) 2.09
ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med (2011) 2.07
A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene (2005) 2.05
The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell (2007) 2.05
Human and mouse oligonucleotide-based array CGH. Nucleic Acids Res (2005) 2.03
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol (2010) 2.01
Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet (2009) 1.96
Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer. Genome Res (2012) 1.95
Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell (2010) 1.88
A role for common genomic variants in the assessment of familial breast cancer. J Clin Oncol (2012) 1.80
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer (2008) 1.76
Copynumber: Efficient algorithms for single- and multi-track copy number segmentation. BMC Genomics (2012) 1.74
Cancer genetics of epigenetic genes. Hum Mol Genet (2007) 1.72
Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. Leuk Res (2006) 1.71
Oncogenic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas. J Pathol (2010) 1.68
A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet (2013) 1.67